Efficacy and safety of consolidation durvalumab after chemoradiation therapy for stage III non-small-cell lung cancer: a systematic review, meta-analysis, and meta-regression of real-world studies

Article Oncology

Prognostic impact of pneumonitis after durvalumab therapy in patients with locally advanced non-small cell lung cancer

Ari Nishimura et al.

Summary: This study retrospectively assessed data from 82 Japanese patients with LA-NSCLC who received durvalumab after chemoradiotherapy, finding that pneumonitis may have prognostic implications for progression-free survival in these patients.

INVESTIGATIONAL NEW DRUGS (2022)

添加到收藏夹

Article Oncology

Risk factors for immune checkpoint inhibitor-related pneumonitis in non-small cell lung cancer

Yencheng Chao et al.

Summary: This retrospective study assessed NSCLC patients receiving ICIs to identify risk factors for immune checkpoint inhibitor-related pneumonitis (CIP). The study found that a history of COPD, tumor PD-L1 expression >= 50%, and low baseline IL-8 levels were independently associated with an increased risk of CIP. A nomogram model was developed to predict the incidence of CIP, showing good predictive accuracy.

TRANSLATIONAL LUNG CANCER RESEARCH (2022)

添加到收藏夹

Article Oncology

79MO PACIFIC-R: Real-world characteristics of unresectable stage III NSCLC patients treated with durvalumab after chemoradiotherapy

F. McDonald et al.

Journal of Thoracic Oncology (2021)

添加到收藏夹

Review Surgery

The PRISMA 2020 statement: An updated guideline for reporting systematic reviews

Matthew J. Page et al.

Summary: The PRISMA 2020 statement, an updated version of the 2009 statement, includes new reporting guidance that reflects advances in research methods. This article introduces the PRISMA 2020 27-item checklist and related information.

INTERNATIONAL JOURNAL OF SURGERY (2021)

添加到收藏夹

Article Oncology

Durvalumab After Concurrent Chemoradiotherapy in Elderly Patients With Unresectable Stage III Non-Small-Cell Lung Cancer (PACIFIC)

Mark A. Socinski et al.

Summary: Based on a post-hoc 70-year age threshold, consolidation durvalumab improved PFS and OS in elderly patients with manageable safety and no detrimental impact on patient-reported outcomes. Grade 3/4 and serious adverse events were more common in patients aged over 70 compared to placebo.

CLINICAL LUNG CANCER (2021)

添加到收藏夹

Article Oncology

Clinical outcomes in stage III non-small cell lung cancer patients treated with durvalumab after sequential or concurrent platinum- based chemoradiotherapy - single institute experience

Martina Vrankar et al.

Summary: This study retrospectively analyzed survival data of patients with unresectable stage III non-small cell lung cancer treated with durvalumab, showing that this treatment regimen is both effective and well tolerated.

RADIOLOGY AND ONCOLOGY (2021)

添加到收藏夹

Article Oncology

Durvalumab after concurrent chemotherapy and high-dose radiotherapy for locally advanced non-small cell lung cancer

Yosef Landman et al.

Summary: This study reports the clinical experience of using durvalumab after high-dose radiotherapy in stage III NSCLC patients, with findings of treatment-related adverse events and local-regional failure rate in the cohort.

ONCOIMMUNOLOGY (2021)

添加到收藏夹

Article Oncology